Polly A. Niravath, MD

Assistant Professor of Clinical Medicine in Oncology, Academic Institute
Houston Methodist
Weill Cornell Medical College


TBCRC023: A randomized phase II neoadjuvant trial of lapatinib plus trastuzumab without chemotherapy for 12 versus 24 weeks in patients with HER2-positive breast cancer
on behalf of the Translational Breast Cancer Research Consortium 2020, Clinical Cancer Research, vol. 26, no. 4, pp. 821-827. https://doi.org/10.1158/1078-0432.CCR-19-0851

Comparison of outcomes between metaplastic and triple-negative breast cancer patients
Polamraju, P, Haque, WM, Cao, K, Verma, V, Schwartz, M, Klimberg, VS, Hatch, S, Niravath, PA, Butler, EB & Teh, BS 2020, Breast, vol. 49, pp. 8-16. https://doi.org/10.1016/j.breast.2019.10.003

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
Patel, T, Ensor, Jr. JE, Creamer, SL, Boone, T, Rodriguez, AA, Niravath, PA, Darcourt, J, Meisel, JL, Li, X, Zhao, J, Kuhn, JG, Rosato, RR, Qian, W, Belcheva, A, Schwartz, MR, Kaklamani, VG & Chang, JC 2019, Breast Cancer Research, vol. 21, no. 1, 100. https://doi.org/10.1186/s13058-019-1186-0

Acupuncture and Vitamin D for the Management of Aromatase Inhibitor-Induced Arthralgia
Anand, K & Niravath, PA 2019, Current Oncology Reports, vol. 21, no. 6, 51. https://doi.org/10.1007/s11912-019-0795-1

TBCRC 022: A phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases
Freedman, RA, Gelman, RS, Anders, CK, Melisko, ME, Parsons, HA, Cropp, AM, Silvestri, K, Cotter, CM, Componeschi, KP, Marte, JM, Connolly, RM, Moy, B, Van Poznak, CH, Blackwell, KL, Puhalla, SL, Jankowitz, RC, Smith, KL, Ibrahim, N, Moynihan, TJ, OSullivan, CC, Nangia, J, Niravath, PA, Tung, N, Pohlmann, PR, Burns, R, Rimawi, MF, Krop, IE, Wolff, AC, Winer, EP & Lin, NU 2019, Journal of Clinical Oncology, vol. 37, no. 13, pp. 1081-1089. https://doi.org/10.1200/JCO.18.01511

Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia
Niravath, PA, Hilsenbeck, SG, Wang, T, Jiralerspong, S, Nangia, J, Pavlick, A, Ademuyiwa, F, Frith, A, Ma, C, Park, H, Rigden, C, Suresh, R, Ellis, M, Kent Osborne, C & Rimawi, MF 2019, Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-019-05319-4

Omission of radiation therapy following breast conservation in older (=70 years) women with T1-2N0 triple-negative breast cancer
Haque, WM, Verma, V, Hsiao, KY, Hatch, S, Arentz, C, Szeja, S, Schwartz, M, Niravath, PA, Bonefas, E, Miltenburg, D, Butler, EB & Teh, BS 2019, Breast Journal. https://doi.org/10.1111/tbj.13443

A Behavior-Modification, Clinical-Grade Mobile Application to Improve Breast Cancer Survivors' Accountability and Health Outcomes
Stubbins, R, He, T, Yu, X, Puppala, M, Ezeana, CF, Chen, S, Valdivia y Alvarado, M, Ensor, J, Rodriguez, A, Niravath, P, Chang, J, Wong, STC & Patel, T 2018, JCO Clinical Cancer Informatics, no. 2, pp. 1-11. https://doi.org/10.1200/CCI.18.00054

Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis
Ayyagari, R, Tang, D, Patterson-Lomba, O, Zhou, Z, Xie, J, Chandiwana, D, Dalal, AA & Niravath, PA 2018, Current Medical Research and Opinion, vol. 34, no. 9, pp. 1645-1652. https://doi.org/10.1080/03007995.2018.1479246

Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2- Advanced Breast Cancer
Dalal, AA, Gauthier, G, Gagnon-Sanschagrin, P, Burne, R, Guérin, A, Niravath, PA & Small, T 2018, Advances in Therapy, vol. 35, no. 9, pp. 1356-1367. https://doi.org/10.1007/s12325-018-0764-3

Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer
Guérin, A, Goldschmidt, D, Small, T, Gagnon-Sanschagrin, P, Romdhani, H, Gauthier, G, Kelkar, S, Wu, EQ, Niravath, PA & Dalal, AA 2018, Advances in Therapy, pp. 1-14. https://doi.org/10.1007/s12325-018-0740-y

Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2- Metastatic Breast Cancer
Dalal, AA, Gagnon-Sanschagrin, P, Burne, R, Guérin, A, Gauthier, G, Small, T & Niravath, PA 2018, Advances in Therapy, pp. 1-11. https://doi.org/10.1007/s12325-018-0701-5

Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2– Metastatic Breast Cancer:: A Network Meta-analysis
Ayyagari, R, Tang, D, Patterson-Lomba, O, Zhou, Z, Xie, J, Chandiwana, D, Dalal, AA & Niravath, PA 2018, Clinical Therapeutics, vol. 40, no. 4, pp. 628-639.e3. https://doi.org/10.1016/j.clinthera.2018.03.004

Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study
Goldschmidt, D, Dalal, AA, Romdhani, H, Kelkar, S, Guerin, A, Gauthier, G, Wu, EQ, Niravath, PA & Small, T 2018, Advances in Therapy, pp. 1-12. https://doi.org/10.1007/s12325-018-0676-2

Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women
Gauthier, G, Gagnon-Sanschagrin, P, Guérin, A, Burne, R, Small, T, Niravath, PA & Dalal, AA 2018, Advances in Therapy, pp. 1-12. https://doi.org/10.1007/s12325-018-0689-x

Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?
Ekinci, E, Nathoo, S, Korattyil, T, Vadhariya, A, Zaghloul, HA, Niravath, PA, Abughosh, SM & Trivedi, MV 2018, Journal of Cancer Survivorship, pp. 1-9. https://doi.org/10.1007/s11764-017-0674-4

Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer
Zhou, Z, Tang, DH, Xie, J, Ayyagari, R, Wu, E & Niravath, PA 2017, Advances in Therapy, vol. 34, no. 12, pp. 2566-2584. https://doi.org/10.1007/s12325-017-0644-2

Current challenges associated with next-generation sequencing of breast cancer - Reply
Niravath, PA, Cakar, B & Ellis, M 2017, JAMA Oncology, vol. 3, no. 9. https://doi.org/10.1001/jamaoncol.2017.0665

Challenges of measuring accurate estradiol levels in aromatase inhibitor-treated postmenopausal breast cancer patients on vaginal estrogen therapy
Niravath, PA, Bhat, R, Al-Ameri, M, AlRawi, A, Foreman, C & Trivedi, MV 2017, Pharmacology Research and Perspectives, vol. 5, no. 4, e00330. https://doi.org/10.1002/prp2.330

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
Ma, CX, Bose, R, Gao, F, Freedman, RA, Telli, ML, Kimmick, G, Winer, EP, Naughton, M, Goetz, MP, Russell, C, Tripathy, D, Cobleigh, M, Forero, A, Pluard, TJ, Anders, C, Niravath, PA, Thomas, S, Anderson, J, Bumb, C, Banks, KC, Lanman, RB, Bryce, R, Lalani, AS, Pfeifer, JD, Hayes, DF, Pegram, M, Blackwell, K, Bedard, PL, Al-Kateb, H & Ellis, MJC 2017, Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-17-0900

Live Chat Available